July 10, 2023
3 min watch
Save
VIDEO: Cyto-KIK trial examines cabozantinib and cytoreductive nephrectomy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Farshid Sadeghi, MD, discussed data from the Cyto-KIK trial on renal cell carcinoma at American Urological Association Annual Meeting.
Sadeghi, a clinical assistant professor at City of Hope Phoenix, highlighted the study, which examined patients with metastatic renal cell carcinoma being treated by a combination therapy of cabozantinib (Cabometyx, Exelixis) and immunotherapy, undergoing cytoreductive nephrectomy, and subsequently resuming the combination therapy.
“For us as surgeons it’s useful to know that after stopping cabozantinib for 2 weeks, patients can be taken to the operating group,” Sadeghi said.
Reference:
- Runcie K, et al. Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial. Presented at: American Urological Association Annual Meeting; April 28-May 1, 2023; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Disclosures:
Sadeghi reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.